81 related articles for article (PubMed ID: 35243392)
21. Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence.
Aoun F; Bourgi A; Ayoub E; El Rassy E; van Velthoven R; Peltier A
Ther Adv Urol; 2017; 9(3-4):73-80. PubMed ID: 28392836
[TBL] [Abstract][Full Text] [Related]
22. Mortality Risks Associated with Depression in Men with Prostate Cancer.
Crump C; Stattin P; Brooks JD; Sundquist J; Sieh W; Sundquist K
Eur Urol Oncol; 2024 Apr; ():. PubMed ID: 38575410
[TBL] [Abstract][Full Text] [Related]
23. Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis.
Hinojosa-Gonzalez DE; Zafar A; Saffati G; Kronstedt S; Zlatev DV; Khera M
Prostate Cancer Prostatic Dis; 2024 Jan; ():. PubMed ID: 38167924
[TBL] [Abstract][Full Text] [Related]
24. Review of Current Treatment Intensification Strategies for Prostate Cancer Patients.
Wasim S; Park J; Nam S; Kim J
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067321
[TBL] [Abstract][Full Text] [Related]
25. Treatment and Mortality in Men with Localized Prostate Cancer: A Population-Based Study in California.
Sieh W; Lichtensztajn DY; Nelson DO; Cockburn M; West DW; Brooks JD; Chang ET
Open Prost Cancer J; 2013; 6():1-9. PubMed ID: 23997838
[TBL] [Abstract][Full Text] [Related]
26. Clinical Predictors of Overall Survival in Very Elderly Patients With Glioblastoma: A National Cancer Database Multivariable Analysis.
Gendreau J; Mehkri Y; Kuo C; Chakravarti S; Jimenez MA; Shalom M; Kazemi F; Mukherjee D
Neurosurgery; 2024 Jun; ():. PubMed ID: 38940573
[TBL] [Abstract][Full Text] [Related]
27. Adaption and National Validation of a Tool for Predicting Mortality from Other Causes Among Men with Nonmetastatic Prostate Cancer.
Justice AC; Tate JP; Howland F; Gaziano JM; Kelley MJ; McMahon B; Haiman C; Wadia R; Madduri R; Danciu I; Leppert JT; Leapman MS; Thurtle D; Gnanapragasam VJ
Eur Urol Oncol; 2024 Jan; ():. PubMed ID: 38171965
[TBL] [Abstract][Full Text] [Related]
28. The median non-prostate cancer survival is more than 10 years for men up to age 80 years who are selected and receive curative radiation treatment for prostate cancer.
Blood PA; Pickles T
Radiat Oncol; 2007 May; 2():17. PubMed ID: 17511871
[TBL] [Abstract][Full Text] [Related]
29. Patient-reported distress and survival among patients receiving definitive radiation therapy.
Habboush Y; Shannon RP; Niazi SK; Hollant L; Single M; Gaines K; Smart B; Chimato NT; Heckman MG; Buskirk SJ; Vallow LA; Tzou KS; Ko SJ; Peterson JL; Biers HA; Day AB; Nelson KA; Sloan JA; Halyard MY; Miller RC
Adv Radiat Oncol; 2017; 2(2):211-219. PubMed ID: 28740934
[TBL] [Abstract][Full Text] [Related]
30. Shifting the paradigm in high-risk prostate cancer: how good is TNM alone?
Aoun F; Helou E; Albisinni S
Prostate Cancer Prostatic Dis; 2023 Oct; ():. PubMed ID: 37884614
[No Abstract] [Full Text] [Related]
31. Expanding Treatment Options for Older Adults With Prostate Cancer.
Morgans A
JAMA Oncol; 2023 Dec; 9(12):1638-1639. PubMed ID: 37883113
[No Abstract] [Full Text] [Related]
32. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
33. Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis.
Rajwa P; Pradere B; Gandaglia G; van den Bergh RCN; Tsaur I; Shim SR; Yanagisawa T; Laukhtina E; Mori K; Mostafaei H; Quhal F; Bryniarski P; Compérat E; Roubaud G; Massard C; Merseburger AS; Leapman MS; Spratt DE; Saad F; Joniau S; D'Amico AV; Briganti A; Shariat SF; Ploussard G;
Eur Urol; 2022 Jul; 82(1):82-96. PubMed ID: 35465985
[TBL] [Abstract][Full Text] [Related]
34. Treatment Patterns and Overall Survival Outcomes Among Patients Aged 80 yr or Older with High-risk Prostate Cancer.
Fischer-Valuck BW; Baumann BC; Brown SA; Filson CP; Weiss A; Mueller R; Liu Y; Brenneman RJ; Sanda M; Michalski JM; Gay HA; James Rao Y; Pattaras JG; Jani AB; Hershatter B; Patel SA
Eur Urol Open Sci; 2022 Mar; 37():80-89. PubMed ID: 35243392
[TBL] [Abstract][Full Text] [Related]
35. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.
Touijer KA; Karnes RJ; Passoni N; Sjoberg DD; Assel M; Fossati N; Gandaglia G; Eastham JA; Scardino PT; Vickers A; Cozzarini C; Montorsi F; Briganti A
Eur Urol; 2018 Jun; 73(6):890-896. PubMed ID: 29042125
[TBL] [Abstract][Full Text] [Related]
36. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.
Rusthoven CG; Jones BL; Flaig TW; Crawford ED; Koshy M; Sher DJ; Mahmood U; Chen RC; Chapin BF; Kavanagh BD; Pugh TJ
J Clin Oncol; 2016 Aug; 34(24):2835-42. PubMed ID: 27325855
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
